All lobbying filings

THE NICKLES GROUP, LLC

Lobbying for CSL BEHRING LLC · Biotherapeutic company providing recombinant and plasma-derived products.

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · Pennsylvania · House · Senate · $50,000.00 income · posted Jan 20, 2026

Official filing document

Bills named in this filing 5

HR 1476
PLASMA Act
S 694
PLASMA Act
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
HR 591
Defending American Jobs and Investment Act
HR 2423
Unfair Tax Prevention Act

Lobbying activity 4

Medicare/Medicaid

Issues related to plasma based therapies. H.R. 1476 / S. 694, Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act. Issues related to gene therapies. Issues related to value-based payments. Issues related to drug shortages. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to plasma derived products and drug pricing. Issues related to pharmacy benefit management. Issues related to Most Favored Nation drug pricing.

Health Issues

Monitored issues related to medical supply chain and pharmacy benefit management. Monitored issues related to drug pricing. Issue regarding plasma-based therapies.

Taxation/Internal Revenue Code

Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to foreign-based corporations, and corporate taxes. Issues related to the OECD Pillar II exemption for the U.S. H.R. 591, Defending American Jobs and Investment Act, and H.R. 2423, Unfair Tax Prevention Act, as they relate to multinational corporations.

Trade (domestic/foreign)

Issues related to tariffs.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.